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Abstract 
Background: Factor XIII Deficiency (FXIIID) is an inherited rare bleeding disorder with some life threatening 
clinical manifestation including Intracranial Haemorrhage (ICH). Among all polymorphisms found in FXIIID, 
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Thr325Ile gene polymorphism increases probability of ICH 
about 20 fold in patients with FXIII .So, in this study we aimed to evaluate TAFI Thr 325 Ile polymorphism in 
Chorionic villus samples (CVS) of fetuses with positive family history of FXIIID and ICH. Materials and 
Methods: This study was performed on  chorionic villus of pregnant mothers ´ with  positive history of  FXIIID 
accompanied with ICH  in  first-degree relatives of their fetus. All parents of the fetuses were completed consent 
form for doing Prenatal diagnosis (PND). Chorionic villus DNA was extracted from each sample using the DNA 
extraction kit and PCR-RFLP was performed for TAFI Thr 325Ile polymorphism in Exon 4 of FXIII A gene.  
Results: All of 8 fetuses had positive family history of FXIIID.  Seven out of eight fetuses (87.5%) had a family 
member with CNS bleeding due to FXIIID. Four fetuses had history of death due to FXIIID. There were 5 case 
(62.5%) that were homozygote for TAFI Thr 325 Ile, one (12.5%) was heterozygote and two (25%) were non 
mutant. Conclusion: Detection of  TAFI Thr 325 Ile polymorphism by PND program in fetuses with positive family 
history of ICH is seems necessary and it will help to fill many gaps in preventing  life threatening features of FXIIID 
in newborn at the time of delivery by prophilaxy receiving and precautionary measures. 
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Factor XIII deficiency (FXIIID) is an inherited 
rare bleeding disorder (RBD) that was presented with 
different  clinical manifestation such as life-long 
bleeding tendency, recurrent miscarriages, 
spontaneous abortion in affected women, mucosal 
bleeding and life-threatening Intracranial Hemorrhage 
(ICH). ICH is an irreparable outcomes of severe 
FXIIID, and an early diagnosis of the disease followed 
by a long-term prophylactic treatment is crucial  (1-4).  
ICH is an important cause of morbidity and mortality 
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in infancy affected with FXIIID. ICH may occurred 
in the neonatal, perinatal and infant periods (5). 
Cerebral hemorrhage is a kind of common event that 
its relevance to the most genetic disorders  such as 
thrombin activable fibrinolysis inhibitor (TAFI ) was 
evaluated. TAFI is a procarboxypeptidase that 
stabilizes fibrin clots, and  some  mutations in this 
molecule cause increase in plasma level of it  to 60% 
that  can cause thrombotic complications such as  
myocardial infraction and stroke. Thr 325 Ile is one 
of the most common polymorphism of TAFI gene 
that its relevance of stroke was approved  (6, 7). In 
our last study , we concluded that  TAFI Thr325Ile 
gene polymorphism increases probability of  ICH in 
patients with positive  FXIII Trp 187 Arg mutation 
about 20 fold in comparison with control group (2). 
This mutation is the most common  mutation in 
FXIIID in Iranian patients (8). Since the first degree 
relative families of fetuses had approved FXIII Trp 
187 Arg accompanied with CNS bleeding ,thus in 
this study we aimed to evaluate TAFI Thr 325 Ile 
polymorphism in chorionic villus samples of fetuses 
to estimate CNS bleeding and prevent of this event in 
affected fetuses during  birth and after that with long-
term prophylactic treatment. 
Methods 
This descriptive study was carried out on families 
with positive history of FXIIID and CNS bleeding.  
FXIII Trp187Arg mutation (C.559T>C) as a 
mutation related to almost all patients with FXIIID in 
south east of Iran was selected for determination of 
FXIIID for these family members and fetus status. 
Then, families with positive history of FXIIID were 
candidate to undergo to perform prenatal diagnosis 
(PND) of FXIIID. chorionic villus samples (CVS) of 
eight pregnant women in their first trimester who 
referred to hemophilia center  in Sistan and 
Baluchestan Province in southeast of Iran during  
September 2013 to  March 2014 .All of eight fetuses 
had positive history of  FXIIID in their first degree 
relatives .All parents of the fetuses were completed 
consent form .This study was approved by the medical 
ethics committee of Tehran University of Medical 
Sciences .  
 PND process  was done by  radiologist and chorionic 
villus sample (CVS) was given from the amniotic 
cavity of uterus and suitable amount of vilii was 
extracted. 
Chorionic villus  DNA was extracted from each 
sample with the DNA extraction kit (Viogene). The 
quality of obtained DNA was determined by means of 
2% agarose gel electrophoresis.  
FXIII TAFI325Ile Thr polymorphism was amplified 
under standard conditions as shown on table 1.  
The PCR product was digested with SpeI (BcuI) 
(Fermentase Life Sciences, York, UK) according to 
the manufacturer’s instruction. Finally the digested 
products were resolved on a 2% agarose gel containing 
0.5 _g/ml ethidium bromide. 
Results 
All of 8 fetuses had positive family history with 
confirmed FXIIID with Trp 187 Arg. Seven out of 
eight fetuses (87.5%) had a family member with CNS 
bleeding due to FXIIID. Four fetuses(50%) had a 
positive history of death due to FXIIID. Umbilical 
cord bleeding and ecchymosis were positive in all 
members of fetus families.Other demographic and 
clinical manifestations of members of fetus families 
were given  in table 2.  
As shown in figure1,in fetus samples ,we had  5 
cases (62.5%) as the homozygote, one case (12.5%) as 
the  heterozygote and two cases(25%) as the  non 
mutant. 
The first fetus was  heterozygous of Trp 187 
Table 1: Primers and PCR condition for Trp187Arg mutation. 
 







Fragments size after digestion 
(bp) 
Forward :5´-TGC TTC CAG TCCTA GTA GC-3´ 
Reverse: 5´-CAG TTG TAT TACATG TGA CC-3´ 
30 56° 216bp WT:216 
Hetero: 166, 50 
Homo:216, 166, 50 bp fragments   
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Arg mutation and no polymorphism in TAFI 325 Ile 
gene . His/Her parents were heterozygous for these 
mutations. The family had two children with severe 
FXIIID  and also had positive history of death related 
to FXIIID.  
Fetus 2was homozygous of Trp 187 Arg and 
TAFI 325 Ile polymorphism,and his/her parents are 
first degree relatives . This family has a daughter 
with FXIIID clinical manifestations such as bleeding 
from the umbilical cord,  ecchymosis, gum bleeding 
and CNS bleeding . The family  had no death history 
related to  FXIIID. 
The third fetus was without Trp 187 Arg 
mutation and homozygous of TAFI 325 Ile gene 
polymorphism. His/Her parents were heterozygous 
mutation and were first degree relative.  
The fourth embryonic case had no Trp 187 
Arg mutation and homozygous polymorphism of 
TAFI Thr 325 Ile . Her/His parents were heterozygous 
for this mutation, and  they were first degree relatives.  
The fifth fetus was from parents with first 
degree relative family and heterozygous for Trp 187 
Arg mutation . The fetus had no this mutation and 
homozygous polymorphisms of TAFI 325 Ile gene. 
This family had death related to FXIIID and  also had 
clinical manifestation related to FXIIID include 
umbilical cord bleeding, ecchymosis , gum bleeding 
and  CNS bleeding.  
Sixth fetus was heterozygous of Trp 187 Arg 
mutation and heterozygous polymorphisms of TAFI 
325 Ile .His/Her parents were not family relatives, but 
the number of affected members of this family with 
FXIIID was two. Molecular study was showed that the 
mother was homozygous of Trp 187 Arg mutation and 
father was heterozygous. The most important  clinical 
manifestations  related to FXIIID were umbilical cord 
blood, ecchymosis and gum bleeding  in this family. 
The  history of CNS bleeding  and death related to 
FXIIID in this family were negative.  
The Seventh fetus was heterozygous of Trp 187 
Arg  mutation with no polymorphism in TAFI 325 Ile 
gene. His/Her parents  were heterozygous of Trp 187 
Arg mutation. This family has a daughter with FXIIID 
with umbilical cord bleeding, ecchymosis, gum 
bleeding  and CNS bleeding. The family had no death 
related to FXIIID .  
Eighth embryonic sample revealed no mutation 
of Trp 187 Arg mutation and homozygous TAFI 325 
Ile polymorphism .His/Her parents were heterozygous 
for this mutation. The family has three children with a 
severe FXIIID  and the most clinical manifestations of 
the three children were umbilical cord blood, 
ecchymosis and CNS bleeding. The family had two 
deaths related to FXIIID. 
Discussion 
Sistan and Baluchestan Province in southeastern 
of Iran with 352 patients with FXIIID, has the highest 
incidence of the disorder not only in Iran but also in all 
over the world because of high consanguineous 
marriages (8,10). These patients cause a high rate of 
morbidity and mortality among Iranian patients and 
CNS bleeding is the main cause of death among this 
population (11-14). Umbilical cord  bleeding is the 
 
Fig. 1. TAFI polymorphism Thr 325 Ile of 8 
fetuses. L:Ladder 100bp, UD: undigested product,  
1,7: unmutant, 2,3,4,5,8: homozygote ,6: 
heterozygote 
Table 2: Demographic characteristics and clinical 












Pos Pos Pos 1 
Pos Neg Pos 2 
Neg Neg Pos 3 
Pos Pos Neg 4 
Pos Neg Neg 5 
Pos Pos Neg 6 
Pos Neg Neg 7 
Pos Pos Neg 8 
Pos: positive, Neg: Negative 
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most common  clinical manifestation pattern of 
FXIIID in Iranian patients (4). The most important 
clinical manifestation of FXIIID in our study is CNS 
and  umbilical cord blood bleeding, ecchymosis and 
gum bleeding.     
  TAFI ,1040CT(Thr/Ile) is in the coding 
region of the TAFI gene and this polymorphism 
affects both plasma antigen level , its activity and 
stability of TAFI in in vitro .The CC (Thr/Thr) 
genotype was associated with the highest levels of 
TAFI and the TT (Ile/Ile) genotype was associated  
with the lowest ones. Ile-325 variants exhibited an 
antifibrinolysis effect that was 60% greater than that 
of Thr-325 variants (8).  
In our study, we had 5 cases with homozygote 
of TAFI Thr 325 Ile polymorphism .We concluded 
that TAFI Thr325 Ile polymorphism is an important 
prognostic factor of CNS bleeding in patients with 
FXIIID and increases the risk of CNS bleeding by 20 
fold .The bleeding polymorphism of TAFI Thr 325 
Ile in accompanied with Trp 187 Arg  gene mutation 
of FXIII can increase the risk of bleeding in CNS, so 
identification of homozygous of  TAFI Thr 325 Ile 
polymorphism in  fetuses  recommend more 
importance of birth care of the fetus during birth and 
after that , fetus had  this characteristics  (2). Tokgoz 
et al, reported that  there was no  correlation between 
this polymorphism and stroke but Kozian et al 
reported a clear correlation between TAFI C>T1040 
and stroke (16, 17). 
In spite of high prevalence of hemophilia, 
there is no evidence-based guidelines for the 
management of delivery in carriers of hemophilia 
pregnant women . There is different  options for the 
delivery of these  women that  it seems  
recommended vaginal delivery, and cesarean doesn’t 
eliminate  the risk of intracranial hemorrhage in 
newborns with hemophilia . Most studies are about 
hemophilia and cesarean delivery has less 
justification than normal delivery, but due to higher 
frequency of CNS bleeding in patients with FXIIID, 
caesarean is more suitable (18-22). 
Affected women at reproductive age are 
usually complicated by menorrhagia and they are 
highly prone to recurrent miscarriage at their 
pregnancy period (23). So, it is recommended that 
they receive 10IU/Kg Fibrogammin concentrate 
during their pregnancy every two weeks and have 
cesarean delivery. 
 In our study, fetus 2 was homozygous of Trp 
187 Arg and TAFI 325 Ile polymorphism. So, his/her 
susceptibility to bleeding in bleeding polymorphism of 
TAFI 325 Ile is high. Since the mother is homozygous 
for the Trp 187 Arg mutation, it is recommended that 
she receive 10IU/Kg Fibrogammin concentrate during 
her pregnancy every two weeks and have cesarean 
delivery. Also, the baby receive Fibrogammin 
concentrate soon after birth to prevent CNS bleeding  
and other life-threatening bleeding. 
Sixth fetus was heterozygous of Trp 187 Arg  
mutation and heterozygous polymorphisms of TAFI 
325 Ile . Molecular study was showed that the mother 
was homozygous of Trp 187 Arg mutation and father 
was heterozygous. We recommend that  the mother 
receive Fibrogammin concentrate 10 IU/Kg during her 
pregnancy every two weeks and she have cesarean 
delivery to prevent life-threatening bleeding. Security 
measures for the fetus should be done during and after 
birth. 
Our limitation was low related study and  there 
was just one study about PND of FXIIID in the 
literature (24) that we couldn’t discuss  and compare 
more about this subject. We suggest that PND of Trp 
187 Arg mutation of FXIII gene be established with 
TAFI Thr 325 Ile in families in the regions with high 
frequency of FXIIID and CNS bleeding. 
Conclusion 
ICH is a life threatening  complication of  
FXIIID and it is commonly occur in these patients. 
Thus,  detection of  TAFI polymorphism by PND 
program in fetuses with positive family history of ICH 
is necessary and it will fill many gaps in preventing  
life threatening features of FXIIID in newborn at the 
time of delivery by receiving prophilaxy and 
precautionary measures.  
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